

Accepted Manuscript

The Scd6/Lsm14 protein *x*RAPB has properties different from RAP55 in selecting mRNA for early translation or intracellular distribution in *Xenopus* oocytes

Michael Lodomery, John Sommerville

PII: S1874-9399(15)00208-4
DOI: doi: [10.1016/j.bbagr.2015.10.002](https://doi.org/10.1016/j.bbagr.2015.10.002)
Reference: BBAGRM 940

To appear in: *BBA - Gene Regulatory Mechanisms*

Received date: 1 June 2015
Revised date: 3 October 2015
Accepted date: 5 October 2015



Please cite this article as: Michael Lodomery, John Sommerville, The Scd6/Lsm14 protein *x*RAPB has properties different from RAP55 in selecting mRNA for early translation or intracellular distribution in *Xenopus* oocytes, *BBA - Gene Regulatory Mechanisms* (2015), doi: [10.1016/j.bbagr.2015.10.002](https://doi.org/10.1016/j.bbagr.2015.10.002)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

REV2/UNMARKED/DOC

The Scd6/Lsm14 protein *x*RAPB has properties different from RAP55 in selecting mRNA for early translation or intracellular distribution in *Xenopus* oocytes

Michael Lodomery* and John Sommerville**

Biomedical Sciences Research Complex, Biomolecular Sciences Building, University of St Andrews, North Haugh, St Andrews, KY16 9TS, UK.

*Present address: Faculty of Health and Applied Sciences, University of the West of England, Coldharbour Lane, Bristol BS16 1QY, UK.

**Corresponding author (e-mail: js15@st-and.ac.uk)

Running title: Lsm14B function in early oocytes

ABSTRACT

Oocytes accumulate mRNAs in the form of maternal ribonucleoprotein (RNP) particles, the protein components of which determine the location and stability of individual mRNAs prior to translation. Scd6/Lsm14 proteins, typified by RAP55, function in a wide range of eukaryotes in repressing translation and relocating mRNPs to processing bodies and stress granules. In *Xenopus laevis*, the RAP55 orthologue *xRAPA* fulfills these functions. Here we describe the properties of a variant of *xRAPA*, *xRAPB*, which is a member of the Lsm14B group. *xRAPB* differs from *xRAPA* in various respects: it is expressed at high concentration earlier in oogenesis; it interacts specifically with the DDX6 helicase Xp54; it is detected in polysomes and stalled translation initiation complexes; its over-expression leads to selective binding to translatable mRNA species without evidence of translation repression or mRNA degradation. Since both Xp54 and *xRAPA* are repressors of translation, activation appears to be effected through targeting of *xRAPB*/Xp54.

Key words: messenger ribonucleoprotein particles (mRNPs); Scd6/RAP55 proteins; LSM14B-A; Xp54/DDX6 helicase; post-transcriptional control; *Xenopus* oogenesis.

1. Introduction

Throughout its existence, mRNA is associated with a wide range of proteins that determine its history and fate: co-transcriptional processing, nucleocytoplasmic transport, cellular localization and ability to be translated, result from a succession of interactions with protein factors and microRNAs (Muller-McNicoll and Neugebauer, 2013). Although many RNA sequence- and structure-specific proteins have been identified, little is known of the extent of heterogeneity in protein composition across the range of mRNP particles. In developing organisms, substantial amounts of mRNP are formed and stored until required for the synthesis of stage-specific proteins, whereas other mRNPs undergo immediate translation to establish the metabolic machinery (Lai and King, 2013). Not only the timing of translation initiation is determined but also the cessation of translation and mRNA decay. These and more subtle effects on the regulation of translation are incurred through the remodelling of mRNP particles. Key processes include: addition and removal of translation masking proteins, cytoplasmic regulation of poly(A) tail length, binding of translation initiation factors to the 5' cap structure, interaction of proteins bridging the 3' and 5' ends of the mRNA, mRNA localization, decapping and hydrolysis of the mRNA (Balagopal and Parker, 2009).

A paradigm for these various effects has been established from studies on oogenesis and early development of *Xenopus laevis*. Over a period of months, oocytes accumulate large numbers of non-translating, maternal mRNA molecules ($>10^{11}$ / oocyte) that are stored to be mobilized to polysomes during later stages of oogenesis, oocyte maturation and, after fertilization, early embryogenesis. During their storage phase, most of these mRNAs have relatively short poly(A) tails (10-30 residues) at their 3' termini (Cabada et al., 1977). Several abundant proteins are found to be associated with these maternal mRNAs to form large RNA-protein complexes which mostly sediment at 30-80 S and have a buoyant density in CsCl of 1.36 g.cm^{-3} (equivalent to a protein:RNA mass ratio of 4:1).

The four most abundant proteins have apparent (electrophoresis) molecular masses between 50-60 kDa (Darnbrough and Ford, 1981): the two slowest migrating were identified as cold-shock domain Y-box proteins, FRGY2a/b (YB2: Deschamps et al., 1992; Murray et al., 1992) and the next as the DEAD-box RNA helicase Xp54/Dhh1 (Ladomery et al., 1997). The fourth protein, of 52 kDa, described in this report as xRAPB, is identified as a variant of RAP55 which is expressed in a wide range of organisms (Marnef et al., 2009). RAP55 was first identified as an RNA-associated protein expressed in oocytes of

the amphibian *Pleurodeles waltl* (Lieb et al. 1998). Its orthologue is also expressed in *Xenopus* oocytes and is here referred to as *xRAPA*. Both *xRAPA* and *xRAPB*, belong to the Scd6/Lsm14 family (Anantharaman and Aravind, 2004), characterized by a multidomain organization consisting of a conserved N-terminal Lsm domain and varied central and C-terminal regions defined by an FDF domain and RGG repeats (Albrecht and Lengauer, 2004). In this report we examine to what extent structural differences between *xRAPA* and *xRAPB* are reflected in differences in function.

RAP55/*xRAPA* has been shown to act as a translation repressor (Tanaka et al., 2006), as have the core mRNP proteins, YB2a/b (Kick et al., 1987; Matsumoto et al., 1996; Yurkova and Murray, 1997; Sommerville, 1999) and Xp54 (Minshall and Standart, 2004; Minshall et al., 2009), along with other mRNP proteins: CPEB (Minshall et al., 2007), 4-ET (Minshall et al., 2007) and P100/Pat1 (Marnef et al., 2010; Nakamura et al., 2010). However, other proteins, involved in mRNP trafficking and translation activation during oogenesis, have yet to be identified. Here we describe several features of *xRAPB*, which distinguish it from *xRAPA*, specifically in having a key role in the regulation of mRNA metabolism during the early stages of oocyte development.

2. Materials and methods

2.1 Sequencing and cloning

Sequence information for *Xenopus laevis xRAPA* was obtained originally from EST clones BG408666 and BG486665 (European Bioinformatics Institute: www.ebi.ac.uk) which showed 74% protein identity with RAP55 of *Pleurodeles waltii* (UNIPROT Q9YH12; www.uniprot.org; Lieb et al., 1998) and were known to be expressed in oocytes of *X. laevis*. A complete coding sequence was constructed from PCR reactions and later found to be identical at the protein level to that of IMAGE clone 3405473 (I.M.A.G.E Consortium: www.imageconsortium.org). *xRAPB* was initially detected by peptide sequencing of an mRNP protein of 52 kDa isolated from stage I oocytes of *X. laevis*: one of the peptide sequences, M/VEQAV, did not occur in either RAP55 or *xRAPA*, but was later detected in a human clone (UNIPROT Q9BX40) which showed 45% identity with RAP55. *X. laevis* EST clones BI444610 and BG731378 were used to generate more extensive and overlapping sequences which were found to form a complete 5' insert in IMAGE clone 3473035 and a complete 3' insert in IMAGE clone 4674033, with a 299 bp overlap between them.

2.2 Expression vectors

PCR copies from cDNA clones encoding complete sequences of *xRAPA* and *xRAPB* were inserted into the pCS2*mt-SGP vector between the unique *Eco* RI site immediately downstream of the 6-times myc epitope and the *Xba* I site immediately upstream of the in-frame GFP sequence as described previously (Smillie and Sommerville, 2002). Stop codons were retained, or inserted, in a second set of vectors to generate transcripts lacking part or all of the GFP sequence. The pCGT vector expressing the complete sequences of *Xp54* following a leader sequence encoding a T-epitope has been described (Smillie and Sommerville, 2002). All *in vivo* expression was driven from the CMV promoter. For *in vitro* expression, proteins were generated using the T_NT Quick Coupled Transcription/Translation System (Promega, Madison, WI) according to the supplier's instructions. Briefly, 0.5-2 µg of plasmid DNA was used in combination with 20 µCi of [³⁵S]-methionine (Redivue >1000 Ci/mmol; Amersham Biotech. GE Healthcare) and either T7 or SP6 RNA polymerase (Promega). After incubation at 30°C for 90 min., the reactions were filtered through Sephadex G-50 (GE Healthcare) by centrifugation in micro-pipette tips to separate the products from unincorporated radioactivity and small molecules. The integrity of radiolabelled products was checked by SDS-PAGE/autoradiography. Quantitation of incorporation was calculated by sampling aliquots in duplicate on to GF/A glass fibre filters (Whatman, GE Healthcare), with and without TCA precipitation and followed by scintillation counting according to supplier's instructions (Promega).

2.3 Morpholinos

Antisense morpholinos (Gene Tools, Philomath, OR) were directed against RNA sequences adjacent to translation start site (bold, where included):

<i>Xp54</i> mRNA	3' TACT CGTGGCGGTCTTGTCTCTTGG	5'
YB2 mRNA	3' CCTCG TACT CACTCCGCCTTCGGGC	5'
<i>xRAPB</i> mRNA	3' GGTATCAGGTTTCTGCTCGTAG TAC	5'
<i>xRAPA</i> mRNA	3' GTAGGTAGGCCCTCTATCC TACT CG	5'
pCS transcripts	3' GTTCGATGAACAAGAAAAACGACCT	5'
pCTG transcripts	3' TAC CGAAGATCCTACCGTAGCTACT	5'
Control	3' CCTCTTACCTCAGTTACAATTTATA	5'

All injected antisense morpholinos showed specific down-regulation of both endogenous and recombinant forms of the target proteins. No deleterious effect on oocytes were observed.

2.4 Oocyte isolation and extraction

Ovary was excised from immature *X. laevis* and oocytes were released and maintained in OR-2 medium and sorted into individual stages as described in detail (Sommerville, 2010). Pools of ~1000, 400, 100 and 40 oocytes, of stages I, II, III and IV were homogenized in HB: 0.1 M NaCl; 2 mM MgCl₂; 2 mM dithiothreitol, 20mM Tris-HCl, pH 7.5. Yolk and lipid were extracted with 1,1,2-trichlorotrifluoroethane (Evans and Kay, 1991). After centrifugation at 10,000 rpm for 15 min at 0°C in a Sorvall SS-34 rotor, the clarified supernatant (SN10) was carefully removed. The extracts were maintained at <2°C throughout and adjusted to 40 units/μl RNasin (Promega) and where appropriate 5 mM EDTA (Sigma). Poly(A⁺) RNP was bound to and eluted from oligo(dT) cellulose (Type 7; Pharmacia, GE Healthcare) as described previously (Ladomery et al., 1997). Typical recovery of poly(A⁺) RNP from early stage oocytes was 250-350 μg/ml eluate.

2.4 Primary antibodies

Poly(A)⁺RNP from early (stage I) oocytes was separated into a heat stable supernatant containing YB2a/b (Deschamps et al., 1992) and a heat-labile precipitate containing principally Xp54 and xRAPB. Antibodies were raised against the renatured proteins from these two fractions. Rabbits producing anti-YB2 generally gave equal reactivity to the a and b forms. Rabbits producing antibodies to the heat-labile proteins gave variable immuno-reactivities, either against Xp54 or xRAPB. Antibodies specific for Xp54 and p52 (xRAPB) were raised against gel-isolated proteins which were renatured by staged dilution from 8M urea into HB (Ladomery et al., 1997; Sommerville and Ladomery, 1996). Rabbit anti-ERK2 was obtained from Santa Cruz Biotech. (Santa Cruz, CA) rabbit anti-phospho-MAP kinase from Cell Signalling (Danvers, MA). Rabbit anti-CPEB was kindly supplied by Laura Hake. Mouse monoclonal antibodies to the c-myc epitope (clone 9E10, Sigma-Aldrich, St Louis, MO) and the bacteriophage T7 epitope (Novagen, Merck, Darmstadt) were used as recommended.

2.6 Oocyte injection and radiolabelling

Stage IV oocytes from albino females were randomly distributed into four sets of 40-50 oocytes and each set was colour-coded using vital stains as described (Sommerville, 2010). The different sets were used for injection of different expression vectors or morpholinos or as controls. For over-expression studies, 10 nl aliquots containing ~10 pg of purified

plasmid DNA were injected into the visible nucleus of colour-coded albino oocytes. Alternatively, RNA transcribed with T3 or T7 polymerase (MessageMachine, Ambion, Waltham, MA) from linearized vectors (10 μ g in 20 nl) was injected into the cytoplasm. Antisense probes were synthesized by the same method but labeled with 32 [P]-CTP (0.1 mCi/ml at >1000 Ci/mmol; Amersham). For knock-down expression, antisense or control morpholinos (5 ng in 20 nl aliquots) were injected into the cytoplasm. After injection the oocytes were pooled and incubated together in OR-2 at room temperature (20-22 $^{\circ}$ C) for periods of 6 to 36 h. For metabolic labelling of proteins, sets of 25 colour-coded oocytes from each injection treatment were pooled and labelled by addition of 30 μ l of [35 S]methionine (0.1 mCi/ml at >1000 Ci/mmol; Amersham) to a total volume of 3 ml of OR2 in 30 mm diameter plastic dishes. At each time point, 5 oocytes of each colour were removed with a minimum of liquid and rinsed twice in 2 ml of OR2 before transfer to a 0.5 ml centrifuge tube and frozen on dry ice. Quantitation of [35 S]methionine incorporation/protein synthesis was carried out as described (Keiper and Rhodes, 1997).

2.7 Immunoblotting

Proteins, equivalent to one oocyte, were separated by SDS-PAGE, transferred to nitrocellulose (0.45 micron, Pierce Biotech. Thermo Fisher) and immunoblotted as described previously (Ryan et al., 1999). Primary antisera or IgG were used at 1:5,000 or 1:10,000, secondary antibodies were goat-anti-rabbit or goat-anti-mouse IgG conjugated to IR Dye 800CW (Li-COR, Odyssey Biosciences, Lincoln, NE) and were all used at 1:40,000. Fluorescent bands were recorded using an Odyssey (Li-COR, Clx) infrared imaging system. All immunoblots shown are representative of those obtained from at least two experiments.

2.8 Immunostaining

Xenopus laevis ovary was fixed in 2% trichloroacetic acid, dehydrated, embedded in wax and sectioned on to glass slides. Dewaxed sections were rinsed with PBST, incubated for 1 hour at 20 $^{\circ}$ C with anti-p54 diluted 1:200 in 10% FCS/PBST, rinsed five times in PBST for 10 min, then incubated with FITC-conjugated anti-rabbit IgG (Chemicon) diluted 1:200 in 10% FCS/PBST. After rinsing in PBST a further five times, the sections were mounted in 20% glycerol / PBST and viewed using an Olympus BX51 fluorescence microscope fitted with an SIS View Firewire CC-12 digital camera (Olympus Soft Imaging, 48149 Munster, Germany).

2.9 Immunoprecipitation

Antibodies were linked to ProSep-vA beads (Millipore, Watford, UK) and proteins or mRNP bound from HB containing 0.05% NP-40 (Sigma) and released as described previously (Ryan et al., 1999).

2.10 UV crosslinking

Samples of poly(A)⁺RNP (25-35 μ g in 100 μ l HB) were placed in a silicone-treated glass depression tray seated on ice and irradiated with 254-nm light at 6,000 μ W.cm⁻² for 5 min to establish protein-RNA crosslinks or 30 min to produce (more extensive) protein-protein crosslinks. Half of irradiated samples were treated with 1 mg/ml ribonuclease A at 37°C for 30 min to resolve close protein-protein association.

2.11 Rate sedimentation analysis

Clarified oocyte extracts and poly(A)⁺ fractions were layered on 10-25% glycerol gradients made up in: 0.1 M NaCl; 2 mM MgCl₂; 2 mM dithiothreitol; 20 mM Tris-HCl, pH 7.5 plus 0.05% NP-40, 40 units/ml RNasin, with and without 50 μ g/ml cycloheximide. For ribosome dissociation, MgCl₂ was replaced with 5 mM EDTA. After centrifugation at 36,000 rpm in a 6 x 5 ml swing-out rotor (Beckman SW50Ti) at 0°C for 2-3 hours, the tube contents were fractionated. Fractions were analysed for proteins by immunoblotting. Sedimentation rates were calculated using 80S ribosomes and 60S and 40S ribosomal subunits run in parallel gradients and scanned through a flow cell measuring absorbance at 254 nm.

2.12 Density gradient centrifugation

Unfixed poly(A)⁺RNP samples (50-100 μ l) were layered on preformed gradients of 6-48% Cs₂SO₄ in 0.1% NP40 (Sigma) and 50 mM sodium phosphate, pH 7.0. After centrifugation at 35,000 rpm for 16 h at 18°C in a Beckman SW50Ti rotor, the tube contents were fractionated. Density values were obtained by refractometry. Each fraction was diluted with 3 vol. dH₂O, then RNP and proteins were ethanol precipitated, for protein extraction with addition of 10 μ g of cytochrome C and for RNA extraction with 10 μ g of yeast tRNA as carriers. Proteins were recovered from precipitated fractions by standard preparation procedure for SDS-PAGE. RNA was recovered by SDS-protease treatment and standard phenol extraction. Unfixed poly(A)⁺RNP was also separated on preformed CsCl gradients, formed and analysed as above.

2.13 RNA extraction, hybridization and RT-PCR

RNA was isolated extracts of 25 oocytes or acetone- or ethanol-precipitated gradient fractions or from immunoprecipitates raised in 250 µg HB plus 40 units/□l RNasin and from their supernatants, by addition of SDS to 1% followed by extractions with equal volumes of phenol-chloroform-isoamyl alcohol then chloform-isoamyl alcohol. 1/10th volume of 5M sodium acetate and 20 µg transfer RNA (Sigma) were added to the extracts and RNA was ethanol precipitated. Dried pellets were raised in RNase-free H₂O. RNA for hybridization analysis was either separated by gel electrophoresis and transferred to nylon membranes or applied directly to the membranes using a Hybri-Slot Manifold (BRL, Bethesda) and hybridized with ³²[P]-CTP labelled antisense probes essentially as described (Sheets et al., 2010). RNA as a template for two-stage RT-PCR was used with random hexamers in the ImProm-IITM Reverse Transcription System (Promega) to generate cDNA followed by amplification with GoTaqTM Master Mix (Promega) as specified by the manufacturer. Gene-specific primer pairs were used to generate products of 300-400 bp after 32 cycles. Products were analysed by electrophoresis on agarose gels as described (Huber and Zhao, 2010).

Gene specific primer pairs:

Nuclear actin (F): 5'CTCACCTGAAGTATCCCATTG; (R): 5'GAAGCAGCTGTTGCCATTT
 β-tubulin (F): 5'CCCAACAACGTTAAGACCG; (R): 5'CCTCCTCTTCCCCTTCCT
 Cyclin B1 (F): 5'CTTTGGCTGGAAGAGGGTTG; (R): 5'CTGACTGCTTGTGCATCCTCA
 D7 (F): 5'CCCTAAACAGGAGCTTGATCTG; (R): 5'CTGCACCATGGGTTTGTATTTG
 EF1α (F): 5'GGAGAATTTGAGGCTGGTATCT; (R) 5'GAGTCGTAGAGGCTTGTTAGTG
 HDAC (F): 5'CGGTTACGGGATGGGATTGAC; (R): 5'GTTGGATGGGCTGATGTGGAAG
 HIM (F): 5'CTGAGGGAGGCAACAAGGAAAAT; (R): 5'CTGCTCTGCATTTGGGTCTAC
 Mos (F): 5'GTGGCGCTGAAGAAGGTAAG; (R): 5'ATAGGCCACTACCGCATAGA
 Nanos1 (F): 5'CTGCAGCCTCAGAGAGAAGG; (R): 5'CCACACAAAGGGCAAGTGTA
 rp-L14 (F): 5'GTCGTACCAACTCCAGTTTCA; (R): 5'GTAGACTTCACGGGCCTTAC
 Vg1 (F): 5'CCATACCCGCTGACAGAAATA; (R): 5'CAGCTAACAGTCAAGGCAAATC
 Xcat2 (F): 5'GCTTTGACTCATGGAGCGAC; (R): 5'GCCGAGTGAGACATCAGTGT
 YB1 (F): 5'CAGTGTGGGAGATGGTGAAC; (R): 5'GAACTGGAGCATTGGAGTATTG

3. Results

3.1 Identification and expression of *xRAPB*

The original guinea pig antibody raised against recombinant RAP55 recognized three proteins in oocyte extracts from *Pleurodeles waltl* with apparent masses of 140, 68 and 56 kDa, but only one protein from *Xenopus laevis* with a mass of 52 kDa (Lieb et al., 1998).

The 68 kDa protein was named RNA-associated protein 55 (the predicted mass of the sequenced clone being 55 kDa). The rabbit antibody raised against a 52 kDa protein isolated from *Xenopus* mRNP (Sommerville and Ladomery 1996) recognizes only the 52 kDa *Xenopus* protein and the 56 kDa protein from *Pleurodeles* (Fig. 1A). Subsequent cDNA cloning, based on peptide analysis of the 52 kDa protein, eventually identified it as a shorter variant of RAP55, one which we named RapB/xRAPB (Weston and Sommerville, 2006; Marnef et al., 2009). The relationships between these proteins, including a form identical to xRAPB but with a single internal deletion (xRAP42; Arthur et al., 2009), are indicated (Fig. 1B).

Immunoblotting of extracts from developing oocytes using anti-p52/anti-xRAPB shows highest reactivity with early stages (I-II), with decreasing signal as oogenesis proceeds (Fig. 1C, top panel). Quantitation of the encoding mRNA/oocyte mass by RT-PCR reveals a similar pattern (Fig. 1C, bottom panel). However, on a per oocyte basis, the amount of xRAPB-encoding mRNA increases through oogenesis, indicating that expression of xRAPB, itself, is subject to translational control.

Immunostaining of ovary sections with anti-xRAPB reflects the immunoblotting results, with reaction steadily decreasing from early stage to be low in concentration by late stage (Fig. 1D). It is also apparent that the cognate protein is almost exclusively cytoplasmic, as has been shown for xRAPA (Tanaka et al., 2006).

Immunoblotting of oocyte fractions bound or unbound by oligo(dT)-cellulose shows that the protein detected by anti-xRAPB is bound to an extent similar to *bona fide* mRNP components, such as Xp54, YB2 and CPEB (Fig. 1E). Binding efficiency is similar in the presence of either Mg^{2+} or EDTA, conditions which may influence intermolecular associations. Xp54, YB2 and xRAPB continue to be present in the poly(A)⁺ fractions after progesterone-induced maturation, but at lower levels. Immunoreaction with anti-ERK2 is shown as a non-mRNP control and with anti-pMAPK as an oocyte maturation marker.

All indications are that xRAPB is an integral component of mRNP particles, particularly of a major population present in early oocytes. That xRAPB is a stably-bound component of these particles can be shown by equilibrium gradient centrifugation of unfixed poly(A)⁺ RNP through high salt (15-40% Cs_2SO_4). Immunoblotting of gradient fractions with a mixture of antibodies to recognize the major mRNP proteins shows that xRAPB together with Xp54 remain bound to RNA (at a buoyant density of 1.44 g.cm^{-3}) after much of the YB2 has been stripped off and recovered at around 1.22 g.cm^{-3} (Fig. 1F). That the density peak represents the core of mRNP particles is demonstrated by extraction of RNA from the

gradient fractions and hybridization with labelled probes directed against a range of early-expressed mRNAs, panels of two of which, nucleolin and histone deacetylase (HDACm) are shown (Fig. 1F). Thus the vast majority of hybridization signal corresponds to the position of the *x*RAPB immunostaining signal. For comparison, particles containing all of the major mRNP proteins can be obtained within a single density peak at around 1.39 g.cm⁻³ on banding in CsCl gradients (Fig. 1F). This density in CsCl corresponds to a protein:RNA ratio approaching the value of 4:1 which is normally quoted for intact mRNP (Cummings and Sommerville, 1988). The differential removal of YB2, especially of YB2b, from mRNP in moderate salt conditions (1 M NaCl) has already been noted (Ladomery and Sommerville, 1994) and may help explain better retention of YB2 in CsCl than in Cs₂SO₄.

3.2 Comparison of interactions of *x*RAPA and *x*RAPB with Xp54

Previous results have indicated a direct interaction of *x*RAPB with Xp54 helicase, an interaction that is not evidenced in early-stage oocytes with *x*RAPA (Minshall et al. 2007). Here we extend these observations by examining protein-protein interactions that occur using *in vitro* synthesised *x*RAPA, *x*RAPB and Xp54 (Fig. 2A) and compare the results with those obtained through crosslinking of proteins within native RNP particles.

Interaction of *x*RAPB with Xp54 can be shown by reciprocal immunoprecipitation from combinations of the *in vitro*-synthesized proteins. Incubation of *x*RAPB with Xp54 and *x*RAPA with Xp54 was followed by binding and elution from immobilized anti-Xp54 and anti-*x*RAPB. Autoradiographs show that anti-Xp54 co-precipitates *x*RAPB much more effectively than *x*RAPA (Fig. 2B, top) and that anti-*x*RAPB co-precipitates Xp54 with *x*RAPB but much less with *x*RAPA (Fig. 2B, bottom).

That *x*RAPB and p54 make close contacts *in vivo* can be shown by u.v.-crosslinking of native mRNP particles from early-stages (Fig. 2C). Here, both *x*RAPB and Xp54 are found in complexes with identical mobilities on SDS-PAGE at about 110 kDa, even on using heat-treated pellets which lack YB2 and mRNA and are reacted simultaneously with anti-*x*RAPB and anti-Xp54. This *M_r* value corresponds with the interpretation of the formation of heterodimers. These complexes are not affected by ribonuclease treatment after irradiation. In comparison, other mRNP components (eg. YB2a/b) form differently-migrating complexes (right panel). Larger complexes running at the top of the gel and detected with anti-Xp54 and anti-YB2, but not with anti-*x*RAPB, are disaggregated on

ribonuclease treatment. This observation suggests that *xRAPB*, unlike *Xp54* and *YB2*, may have no direct RNA-binding activity.

These results indicate that, during early oogenesis, *xRAPB* is a natural partner protein for the RNA helicase *Xp54*, perhaps in selecting mRNAs for early translation.

3.3 *xRAPB* expression complements *Xp54* expression in the formation of mRP particles

In order to study the interaction of *xRAPB* and *Xp54* in the assembly of mRNP particles, recombinant forms of the proteins were expressed *in vivo* after injection into mid-stage, oocytes. T7-tagged *Xp54* and myc-tagged *xRAPB*, or myc-tagged *xRAPA*, were co-expressed from CMV-driven vectors injected directly into oocyte nuclei. This approach has the advantage of accessing the complete, natural pathway of gene expression and therefore is more likely to produce correctly located and functioning proteins (Braddock et al., 1994; Matsumoto et al., 1998). The compositions of the three recombinant proteins, showing the location of their functional domains, are represented in Fig. 3A.

The relative rates of synthesis of the epitope-tagged proteins were compared with the levels of endogenous proteins by immunoblotting with anti-*Xp54* and anti-*xRAPB*. It was found that equivalence for both was reached at between 24 h and 48 h post-injection of the relevant vector (Fig. 3B). Interestingly, for both proteins, as the level of tagged protein increased, the level of endogenous protein showed a corresponding decline, indicating homeostatic regulation.

The shorter-term kinetics of co-expression of the recombinant proteins were examined by injecting run-off transcripts (using T3 or T7 RNA polymerase) into the cytoplasm of mid-stage oocytes and sampling for immunoblotting at two-hourly intervals. As can be seen (Fig. 3C), myc-tagged-*xRAPB* is detected and accumulated from 4 h post-injection. However, co-expression with T7-tagged-*Xp54* leads to earlier detection of both *Xp54* and *xRAPB* (from 2 h). This co-operative effect was then exploited by examining mRNP assembly after nuclear co-injection.

As with co-precipitation of *xRAPB* and *Xp54* from proteins synthesized *in vitro* (Fig. 2 B), immunoprecipitation from lysates of oocytes co-expressing myc-tagged *xRAPB* and T7-tagged *Xp54* *in vivo*, showed co-precipitation using anti-myc epitope, anti-T7 epitope, anti-*Xp54* or anti-*xRAPB* (Fig. 3D). Non-immune rabbit serum was used as a negative control. The extent of co-precipitation using anti-epitope tags to detect *de novo*-synthesized myc-*xRAPB* and T7-*Xp54* corresponded well with co-precipitation results

using antibodies directed against the native proteins. However, antibodies recognizing Xp54 were more efficient in co-precipitating *x*RAPB than were the antibodies recognizing *x*RAPB in co-precipitating Xp54. This would be expected if Xp54 bound to *x*RAPB constitutes only a sub-fraction of the Xp54 population, assuming that the ectopically expressed proteins behave in a manner similar to their endogenous equivalents.

Stored mRNP particles typically sediment at 30-80S in rate-zonal gradients (Darnbrough and Ford, 1981). In order to check whether *x*RAPB is actively incorporated *in vivo* into newly-synthesized particles, epitope-tagged *x*RAPB and Xp54 were co-expressed in mid-stage oocytes and their distribution was analysed after sedimentation in glycerol gradients. Assembly of newly synthesized *x*RAPB into mRNP particles was found to correspond (in size distribution) to that of newly synthesized Xp54 (Fig. 3E). Pre-treatment of the oocyte extract with ribonuclease resulted in both *x*RAPB and Xp54 being resolved in smaller molecular complexes. In contrast, *x*RAPA, co-expressed with Xp54, appeared to prevent Xp54 from entering into larger mRNP particles, again pointing to the co-operation of *x*RAPB and Xp54, but a dislocation of *x*RAPA and Xp54, in early mRNP assembly (Fig. 3F). It should be noted that immunostaining of all three components can be detected in pelleted 80S+ material, their continued presence here after ribonuclease treatment (Fig. 3E,F, bottom panels) probably due to aggregation of released proteins.

3.4 Comparison of the effects of knock-down and over-expression of *x*RAPA and *x*RAPB

Previous studies have shown that *Xenopus x*RAPA represses translation in an *in vitro* system and also *in vivo* in oocytes when tethered to a reporter RNA (Tanaka et al., 2006) as has Xp54 (Minshall et al. 2001, 2004). However, injection of anti-*x*RAPB IgG into oocytes does not interfere with the formation of masked reporter transcripts, whereas injection of anti-Xp54 IgG releases masked transcripts for translation (Braddock et al. 1994), indicating that *x*RAPB may not act as a translation repressor. In order to explore this possibility, we compared the effects of knockdown and over-expression of *x*RAPB, *x*RAPA and Xp54.

As expected, injection of anti-sense morpholinos (a/sMOs) into the cytoplasm of oocytes expressing recombinant *x*RAPB and Xp54 from nuclear vectors greatly inhibits their synthesis (Fig. 4A), but injection of a/sMOs directed against the endogenous mRNAs encoding these protein also results in inhibition (Fig. 4B). No significant MO cross-reactions were detected in comparing all of the targeted proteins. These findings open the possibility of using a/sMOs to examine the effects of depletion of *x*RAPB, *x*RAPA and

Xp54 on translation rates in injected oocytes. As can be seen (Fig. 4C), Xp54 a/sMO significantly increases the rate of protein synthesis, whereas *xRAPB* a/sMO gives slight repression. The effect of *xRAPA* a/sMO differs little from the effect of a non-specific control MO. On comparing the spectrum of labelled proteins by SDS-PAGE / autoradiography (Fig. 4D, right panel) it can be seen that the a/sMO treatments result in differences of general signal intensity: there is no evidence for an increase or decrease in the translation of specific proteins. Also, comparison of the radiolabelling with protein staining in individual tracks indicates that the labelled bands do not fully correspond, either in intensity or migration to the staining pattern. This reflects oocyte stage-specific translation and differential protein stability. Quantitation of track densities are shown in the accompanying table, again indicating that the most significant deviation from the control is the positive effect of anti-sense of Xp54 mRNA.

Results from the reverse experiment, examining the effect of increased expression of *xRAPB*, *xRAPA* and Xp54 on protein synthesis, are shown (Fig. 4E). Here there is a reversal of outcomes, with over-expression of Xp54 resulting in inhibition of protein synthesis and over-expression of *xRAPB* in an apparent activation. *xRAPA* gave no significant difference from the (mock-injected) control. The profiles of newly-synthesized proteins (Fig. 4F) again showed differences in overall intensity. In the autoradiograph shown, the last two track represents synthesis after co-expression of myc-*xRAPB* and T7-Xp54, which can be compared with the expression of these proteins individually. In these tracks the over-expressed myc-*xRAPB* can be discerned at its slower migrating position (white dot and upper arrow), whereas over-expressed T7-Xp54 is obscured in the heavier labelled region of the gel (white dot and lower arrow). Quantitation of track densities confirm a significant inhibition of translation by over-expressed Xp54 and a modest increase in translation of *xRAPB* (this is with the myc-*xRAPB* band contribution subtracted from the total). Co-expression of *xRAPB* with Xp54 leads to moderation of the repressor activity of Xp54 (Fig. 4F). The least we can conclude is that over-expression of *xRAPB* does not inhibit the activity of already translating mRNAs.

3.5 *xRAPB* is associated with translating mRNAs

It might be expected that manipulated changes in translation rate would be reflected in changes in the distribution of mRNP particles, specifically in association with ribosomal components. Rate sedimentation analysis of extracts from mid-stage oocytes containing over-expressed Lsm14 proteins show that the distribution of myc-*xRAPA* remains typical

of mRNPs containing endogenous Xp54 and YB2 (Fig. 5A, broken box area), whereas a significant proportion of the myc-xRAPB signal has moved into the 80-120S region (solid box area) with a much weaker signal in faster sedimenting complexes. The 80-120S complexes are disassembled in the presence of EDTA (Fig. 5B) and have previously been shown to represent stalled translation initiation complexes (Cummings and Sommerville, 1988).

Whereas mRNP particles from early- to mid-stage oocytes have been described as forming a heterogeneous size distribution on rate-sedimentation gradients (Darnbrough and Ford, 1981; Cummings and Sommerville, 1988), native xRAPB is seen to be present in particles with a bimodal distribution, sedimenting in sub-80S and post-120S fractions. This contrasts with Xp54 and YB2, both of which form a continuous distribution across the 80S region (Fig. 5C,E, broken box area) and indicates that mRNP particles free of xRAPB are also present in mid-stage oocytes. On the other hand, the distribution of xRAPB seen here is typical of that of separated stored mRNP and polysomes. Hybridization of gene-specific antisense probes with RNA extracted from the gradient fractions confirms that mRNA not translated during early oogenesis (eg. encoding cyclin B1, Fig. 5C) is not present in putative polysome fractions but, instead, remains in fractions associated with stored mRNA. In contrast, early-translated mRNA (eg. encoding β -tubulin, Fig. 5C) extends into the polysome region, reflecting the bimodal distribution of xRAPB. Support for these distributions representing a distinction between mRNP storage and translation complexes can be seen from gradients of the same extracts pre-treated with EDTA, which result in the total disruption of post-80S RNP with cyclinB1 mRNA now sedimenting with Xp54 and YB2 at less than 60S and the β -tubulin mRNA sedimenting at less than 40S with xRAPB (Fig. 5D). The bimodal distribution of xRAPB is better defined in early-stage oocytes (Fig. 5E), whereas all post-80S signal is absent from ectopically-expressed xRAPB in late-stage and matured oocytes (Fig. 5F, broken box area).

3.6 Identification of mRNA classes found in association with xRAPB

Confirmation of direct interaction of early-expressed mRNA species with xRAPB is obtained from RT-PCR of RNA extracted from immunoprecipitated RNP particles (Fig. 6). In order to standardize precipitation and to minimize potential immunological cross-reaction, both myc-tagged xRAPB and myc-tagged xRAPA were used as the targets for monoclonal anti-myc (cf. Huber and Zhao, 2010). As can be seen (Fig. 6), immunoprecipitates (P) from oocytes expressing myc-xRAPB contained mRNA species

that are being translated in oocytes (for nuclear actin, β -tubulin, EF1a, ribosomal protein L14 and HDACm) but not stored mRNAs that are translated later at oocyte maturation (for cyclin B1 and c-mos), in the egg (for D7) and during early embryogenesis (for somatic YB1 and linker histone H1M). Actively translating mRNAs are not precipitated from oocytes expressing myc-xRAPA, whereas stored mRNAs are precipitated to varying extent. However, this analysis is complicated by instability of some stored mRNAs (eg. encoding cyclin B1 and c-mos), but not of translating mRNAs or embryo-expressed mRNAs (eg. for H1M), in myc-xRAPA-expressing oocytes. Additionally, mRNAs that pass through localization pathways in early- to mid-stage oocytes (encoding Xcat2 and Vg1) but are translationally repressed during oogenesis were also immunoprecipitated along with xRAPB.

All results shown here were generated from the same cDNA templates, the original RNA extracts showing similar amounts of ribosomal RNAs. (Fig. 6.) Furthermore, incorporation of ectopically-expressed xRAP proteins is to be expected to be more efficient in mRNP complexes with a greater rate of turnover.

4. Discussion

Post-transcriptional regulation in the cytoplasm of oocytes falls into several categories including translation activation, distribution of mRNA to specific cellular sites, storage of mRNA in a masked form to be activated at the appropriate stage of development and degradation/recycling of mRNA to retain a metabolic balance. It is against this background that we look for components that determine stage-specific effects, one candidate group being the various forms of the Scd6/Lsm14 family which are present in germ cells and evolutionarily conserved in eucaryotic somatic cells (Marnef et al., 2009).

4.1 xRAPB as an integral component of poly(A)⁺RNP in early-stage oocytes

In this study immunoblots with anti-xRAPB showed that the concentration of xRAPB decreases from early oogenesis to full-growth (Fig. 1C,E), a feature confirmed by immunostaining ovary sections (Fig. 1D), whereas the concentration of the translation repressor xRAPA increases during oogenesis (Tanaka et al., 2006). Cross-reacting antibodies clearly show this reciprocal expression pattern (Minshall et al., 2007). That xRAPB co-isolated with Xp54, YB2 and CPEB (Minshall et al., 2007) in association with polyadenylated mRNA (Fig. 1E) indicated that this mRNP may be capable of entering the translation pathway. These observations can be compared with the timing of

transcriptional activity which starts at maximum in early oocytes and decreases towards full growth and with the steady-state level of mRNA that exists from mid to late oogenesis, maintaining the pool of stored mRNA required for translation during oocyte maturation and early embryogenesis in the absence of further transcription (reviewed, Sommerville, 1990). Thus the availability of *xRAPB* matches the timing of early onset events, not only mRNA translation for oocyte growth and protein storage but also distribution of mRNA to specific cellular sites (Kloc and Etkin, 2005), whereas the availability of *xRAPA* matches the repression and turnover of mRNA and storage of mRNA for later development.

4.2 Interaction of *xRAPB* with the RNA helicase *Xp54*

The ability of *Xp54* and *xRAPB* to interact with each other: as *in vitro*-synthesized proteins (Fig. 2B); as native proteins in early-stage oocytes (Fig. 2C; Minshall et al., 2009): as over-expressed proteins in mid-stage oocytes (Fig. 3D), contrasted with a lack of comparable interaction of *Xp54* with *xRAPA*. Furthermore, co-expression of *Xp54* with *xRAPB* lead to stabilization of *xRAPB* synthesis (Fig. 3C) and incorporation of both proteins into mRNP particles with a heterogeneous range of sizes (Fig. 3E), whereas co-expression *xRAPA* with *Xp54* leads to the incorporation of *xRAPA* to the exclusion of *Xp54*, at least in fast-sedimenting particles (Fig. 3F). All of these results confirm *Xp54/xRAPB* selectivity in the assembly of a specific class of mRNP particles during early- to mid-oogenesis.

It was shown previously that in early oogenesis, YB2a/b are much more stable than *Xp54* and *xRAPB*, which have similar turnover rates (Dixon and Ford, 1982). Here, the stability of the native *Xp54/xRAPB/mRNA* complex and removal of YB2a/b in high salt conditions (Fig. 1F) is consistent with this functional grouping. However, activation of protein synthesis in early-stage oocytes may require binding of suppressor protein or conformational change of any *Xp54* (Minshall et al., 2009) retained on target mRNAs. The modification/stimulus required to suppress *Xp54* activity for translation activation is not known, although *Xp54* phosphorylation (Sommerville, 1990; Weston and Sommerville 2006) and *xRAPB* methylation (Matsumoto et al., 2012) can be considered.

4.3 Involvement of *xRAPB* in promoting translation

Repression of translation by antisense-morpholinos (a/sMOs) was clearly effective on targetted ectopically-expressed mRNA (Fig. 4A), but less so on endogenous mRNA (Fig. 4B). However, on examining the effects of injecting a/sMOs on *in vivo* translation, the Xp54 MO gave a significantly different effect from the *xRAPB* MO. As expected of a translation repressor, inhibition of Xp54 mRNA gave an ~30% up-regulation, whereas inhibition of *xRAPB* mRNA gave an ~18% down-regulation, indicating, at least, that *xRAPB* is not a translation repressor (Fig. 4C,D). The *xRAPA* MO showed little difference from the control MO, indicating that *xRAPA* is not involved in on-going translation. The profile of labelled bands seen on SDS-PAGE/autoradiography appeared not to change, only the overall band intensities (Fig. 4D), indicating that the affected proteins were common to the population of translating mRNAs.

That some competition for translation components was seen on comparing the levels of T7-Xp54 with endogenous Xp54 and of myc-*xRAPB* with endogenous myc-*xRAPB*, where ectopic expression appeared to increase at some expense to the level of their endogenous counterparts (Fig. 3B). Nevertheless, when effects of over-expression of Xp54 and *xRAPB* on *in vivo* translation were examined significant differences were observed in the rate of amino acid incorporation (Fig. 4E), especially with T7-Xp54 giving translation repression (~ 50%) and myc-*xRAPB* giving translation stimulation (~ 30%). However, even allowing for the contribution of the myc-*xRAPB* labelled band on autoradiographs, its subtraction from the track density still gave ~10% overall stimulation by *xRAPB* (Fig. 4F, table). Again we can claim is that, whereas excess Xp54 clearly functions, as shown earlier (Minshall et al., 2001,2004), as a translation repressor, excess *xRAPB* does not.

Rate-sedimentation analysis showed endogenous *xRAPB* to be present in polysomal fractions of extracts taken from early-stage (Fig. 5E) to mid-stage (Fig. 5C) oocytes. The bimodal separation of not only *xRAPB*, but also expressed mRNA (oocyte-specific β -tubulin), and the resolution of both to a single, slow sedimenting mRNP distribution after treatment of extracts with EDTA confirmed this interpretation (Fig. 5D). Of additional interest is that the fractions bridging the bimodal distribution contained high concentrations of Xp54 and YB2 but no visible *xRAPB* (Fig. 5C). These fractions apparently represent an alternative class of mRNP, as do fractions that form an intermediate peak containing stored mRNA (cyclin B1).

In comparison to endogenous activity, myc- over-expressed in mid-stage oocytes showed a much weaker signal in the polysome region, but greater than does myc-*xRAPA*, (Fig. 5A). This is to be expected because of the modest (~10%) increase in overall

translation seen after over-expression (Fig. 4E,F). Instead, the majority of the myc-*xRAPB* signal was seen in the 80-120 S region of the gradient. That this sedimentation class represents the accumulation of stalled translation initiation complexes has been shown previously, in extracts from mid-stage oocytes, to contain, in addition to 80 S ribosomes and poly(A)⁺RNP particles, charged tRNA_{met} (Cummings and Sommerville, 1988). Furthermore, protein staining showed no obvious loss of *xRAPB/Xp54* relative to YB2 in the formation of these complexes (Cummings and Sommerville, 1988), their apparent under-representation here (Fig. 5A) being due to the stronger myc-epitope signal. Again, complex disassembly occurred after EDTA treatment (Fig. 5B). Nevertheless, it must be recognized that myc-*xRAPB* over-expression results in an artificial redistribution of mRNP particles (cf. Fig. 5A with C). This effect was over by late oogenesis and maturation, by which time no incorporation of myc-*xRAPB* into stalled initiation complexes was seen (Fig. 5F).

Retention of *xRAPB* in stored mRNP particles, stalled initiation complexes and polysomes indicates that its removal is not required in progressing through these states of activity. A similar situation has already been reported for ovarian tissue of *Drosophila*, where a proportion of the Scd6/Lsm14 protein Tral isolates with polysomes although the Xp54 orthologue Me31B isolates only in free mRNP particles (Liu et al., 2011). However, in the results presented here, both the masking proteins YB2a/b and the repressor Xp54 were detected in polysomal regions (Fig. 5C,E) but not after EDTA treatment. In the case of YB2, orthologues in mammalian cells (YB1/p50) and *Chironomus* cells (*ctYB1*) can remain associated with translating mRNAs, albeit with lower stoichiometry (Evdokimova and Ovchinnikov, 1998; Soop et al., 2003). As already discussed (Section 4.2), any Xp54 retained may undergo structural modification to release its repression function or be sufficiently neutralized by excess or modified *xRAPB*.

4.4 Identification of mRNAs that bind *xRAPB*

The stability of mRNP complexes incorporating myc-*xRAPB* has a further use in identifying the mRNAs that they contain. That concurrently translated mRNAs are indeed associated with *xRAPB* and not *xRAPA* was shown by analysis of RT-PCR products of RNA co-immunoprecipitated with *xRAPB* and *xRAPA* (Fig. 6). All of the sequences derived from translating mRNAs were detected in *xRAPB* co-precipitates and to a much lesser extent in *xRAPA* co-precipitates. Those tested included mRNAs encoding: structural proteins (oocyte-specific β -tubulin and nuclear actin); translation components (EF1 α and

ribosomal protein L14) and stored enzymes (maternal histone deacetylase, HDACm). In addition, however, a category of mRNAs that are not translated in oocytes was also immunoprecipitated along with *xRAPB*. These are mRNAs localized to the vegetal region in early-stage oocytes: encoding *Xcat2/Nanos1* (Lai et al., 2011) and in mid-stage oocytes: encoding *Vg1* (Kloc and Etkin, 2005). The co-precipitation of *Vg1* mRNA with *xRAPB* is consistent with the previous demonstration that *xRAPB*, together with *xRAPC* (Fig. 1B), *YB2* and *Xp54* can be immunoprecipitated by antibodies recognizing *Vg1*-localizing proteins (Arthur et al., 2009). Here we have shown that early-localized particles containing *Nanos1* mRNA appear also to contain *xRAPB*. Since *Nanos* mRNA is specifically translated in the next generation of precursor germ cells, perhaps *xRAPB*, if still bound, is required for its early activation.

Of the mRNAs not co-precipitated with *xRAPB* (Fig. 6), co-precipitation with *xRAPA* was also absent from those mRNAs not translated until egg formation (D7) or early embryogenesis (somatic *YB1* and maternal linker histone *H1M*). Although the mRNAs to be translated during oocyte maturation (*cyclinB1* and *c-mos*) did appear to have bound *xRAPA*, the mRNAs themselves appear to be unstable. This may well be due to the over-expression of *xRAPA*, known to be a component involved with *Xp54* in the RNA degradation pathway. This highlights a potential limitation of the use of epitope-tagged proteins as a target for immunoprecipitation: although they present optimum antigenicity, their over-expression may lead to metabolic side-effects.

4. 5 Additional functions of *Scd6/Lsm14* proteins

Induction of mRNA degradation by over-expressed *Scd6/Lsm14* has been well documented for a wide range of organisms (Marnef et al., 2009; Balagopal and Parker, 2009) and in vertebrates appears to be essential for the formation of P-bodies. *Xenopus* *xRAPA* has been shown to be present in non-defined cytoplasmic foci in oocytes and to locate to P-bodies when expressed in mammalian cells (Tanaka et al., 2006). Furthermore, tethering of *xRAPA* to a reporter mRNA expressed in late-stage oocytes caused a decrease in the levels of the reporter protein. However, early growth of mouse oocytes is accompanied by the loss of P-bodies and, as with *Xenopus* *Vg1* and *Nanos1*, translocation of mRNP complexes (lacking decapping enzymes) to sub-cortical regions (Flemr et al., 2010) and translationally silent mRNAs in the gametocytes of *Plasmodium* are contained in storage granules defined by the presence of the *p54/DDX6* and *Scd6/Lsm14* orthologues, *DOZ1* and *CITH*, but the absence of RNA degradation factors (Mair et al.,

2010). Thus germ cells may present a special case in the use of p54/DDX6 and Scd6/Lsm14 for mRNA storage and distribution rather than degradation.

Conclusions

The major feature of Scd6/Lsm14 proteins in oogenic/embryonic systems lies in their efficient handling of mRNA through the developmental programme. In *Xenopus* oocytes, at least, this is managed through the involvement of different Lsm14 proteins: xRAPA and xRAPB and possibly others. As argued here, xRAPB is responsible for the selective translation or distribution, from the total pool, of those mRNAs required for oocyte growth and development, whereas xRAPA is required for translation repression, mRNA degradation and storage of those mRNAs required for late oogenesis and meiosis. Since RAPB paralogues might be critical for oogenesis and fertility, their study in other eukaryotes should be well worthwhile.

Acknowledgements

We thank Bernhard Lieb for introducing us to RAP55 and our students: Amanda Miren de Asis, Sharon Fury, Rob Little, Melanie Simpson, Laura Whitney and Andrew Weston for preliminary contributions to this study. The project was supported by The Wellcome Trust.

References

- Albrecht, M. and Lengauer, T. (2004). Novel Sm-like proteins with long C-terminal tails and associated methyltransferases. *FEBS Lett.* 569, 18-26.
- Anantharaman, V. and Aravind, L. (2004). Novel conserved domains in proteins with predicted roles in eukaryotic cell-cycle regulation, decapping and RNA stability. *BMC Genomics*, 5: 45.
- Arthur, P. K., Claussen, M., Koch, S., Tarbashevich, K., Jahn, O., and Pieler, T. (2009). Participation of *Xenopus* Elr-type Proteins in Vegetal mRNA Localization during Oogenesis. *J. Biol. Chem.* 284, 19982-19992.
- Balagopal, V. and Parker, R. (2009). Polysomes, P bodies and stress granules: states and fates of eukaryotic mRNAs. *Curr. Opin Cell Biol.* 21, 403-408.
- Braddock, M., Muckenthaler, M., White, M.R.H., Thorburn, A.M., Sommerville, J., Kingsman, A.J. and Kingsman, S.M. (1994). Intron-less RNA injected into the nucleus of *Xenopus* oocytes accesses a regulated translation control pathway. *Nucleic Acids Res.*, 22, 5255-5264.
- Cabada, M. O., Darnbrough, C, Ford P. J. and Turner, P. C. (1977). Differential accumulation of two size classes of poly(A) associated with messenger RNA during oogenesis in *Xenopus laevis*. *Dev. Biol.* 57, 427-439.
- Cristodero, M., Schimanski B., Heller, M. and Roditi, I. (2014). Functional characterization of the trypanosome translational repressor SCD6. *Biochem J.* 457, 57-67.
- Cummings, A. and Sommerville, J. (1988). Protein kinase activity associated with stored messenger ribonucleoprotein particles of *Xenopus* oocytes. *J. Cell Biol.* 107, 45-56.
- Darnbrough, C. H. and Ford, P. J. (1981). Identification in *Xenopus laevis* of a class of oocyte-specific proteins bound to messenger RNA. *Eur. J. Biochem.* 113, 415-424.
- Deschamps, S., Viel, A., Garrigos, M., Denis, H. and Le Maire, M. (1992). mRNP4, a major mRNA-binding protein from *Xenopus* oocytes is identical to transcription factor FRGY2. *J. Biol. Chem.* 267, 13799-13802.
- Dixon, L.K. and Ford, P.J. (1982). Regulation of protein synthesis and accunulation during oogenesis in *Xenopus laevis*. *Dev. Biol.* 93, 478-497.
- Evans, J.P. and Kay, B.K. (1991). Biochemical fractionation of oocytes. *Methods Cell Biol.* 36, 133-148.

- Evdokimova, V. M. and Ovchinikov, L. P. (1998). Translational regulation by Y-box transcription factor: involvement of the major mRNA-associated protein p50. *Int. J. Biochem. Cell Biol.* 31,139-149.
- Flemr, M., Ma, J., Schultz, R. M. and Svoboda, P. (2010). P-body loss is concomitant with formation of a messenger RNA storage domain in mouse oocytes. *Biol. Reprod.* 82,1008-1017.
- Huber, P.W. and Zhao, W. (2010). Detection of protein-RNA complexes in *Xenopus* oocytes. *Methods* 51,82-86.
- Kick, D., Barrett, P., Cummings, A. and Sommerville, J. (1987). Phosphorylation of a 60 kDa polypeptide from *Xenopus* oocytes blocks messenger RNA translation. *Nucleic Acids Res.* 15, 4099-4109.
- Kloc, M. and Etkin, L. D. (1995). Two distinct pathways for the localization of RNAs at the vegetal cortex in *Xenopus* oocytes, *Development* 121, 287–297.
- Ladomery, M. and Sommerville, J. (1994). Binding of Y-box proteins to RNA: involvement of different protein domains. *Nucleic Acids Res.*, 22, 5582-5589.
- Ladomery, M., Wade, E. and Sommerville, J. (1997). Xp54, the *Xenopus* homologue of human RNA helicase p54, is an integral component of stored mRNP particles in oocytes. *Nucleic Acids Res.*, 25, 965-973.
- Lai, F. and King, M. L. (2013). Repressive translational control in germ cells. *Mol. Rep. Dev.* 80, 665-676.
- Lieb, B, Carl, M., Hock, R., Gebauer, D. and Scheer, U. (1998). Identification of a novel mRNA-associated protein in oocytes of *Pleurodeles waltl* and *Xenopus laevis*. *Exp. Cell Res.*, 245, 272-281
- Liu, L., Qi, H., Wang, J. and Lin, H. (2011). PAPI, a novel TUDOR-domain protein, complexes with AGO3, ME31B and TRAL in the nuage to silence transposition. *Development* 138, 1863-1873
- Mair, G.R. et al. (2010). Universal features of post-transcriptional gene regulation are critical for for Plasmodium zygote development. *PLoS Pathog.* 6, 1-12 doi:10.1371.
- Matsumoto, K., Meric, F. and Wolffe, A. (1996). Translational repression dependent on the interaction of the *Xenopus* Y-box protein FRGY2 with mRNA. *J. Biol. Chem.* 271, 22706-22712.

- Matsumoto, K., Wasserman, K. M. and Wolffe, A. P. (1998). Nuclear history of a pre-mRNA determines the translation activity of cytoplasmic mRNA. *EMBO J.* 17, 2107-2121.
- Matsumoto, K., Nakayama, H., Yoshimura, M., Masuda, A., Dohmae, N., Matsumoto, S. and Tsujimoto, M. (2012). PRMT1 is required for RAP55 to localize to processing bodies. *RNA Biol.* 2012 9, 610-623.
- Marnef, A., Sommerville, J. and Lodomery, M.R. (2009). RAP55: Insights into an evolutionarily conserved protein family. *Interntl. J. Cell Biol.* 5, 977-981.
- Marnef, A., Maldonado, M., Bugaut, A., Balasubramanian, S., Kress M., Weil D, Standart, N. (2010). Distinct functions of maternal and somatic Pat1 protein paralogs. *RNA.* 16, 2094-2107.
- Minshall, N. and Standart, N. (2004). The active form of Xp54 RNA helicase in translational repression is an RNA-mediated oligomer. *Nucleic Acids Res.*, 32, 1325-1334.
- Minshall N., Thom, G. and Standart, N. (2001). A conserved role of a DEAD-box helicase in mRNA masking. *RNA* 7, 1728-1742.
- Minshall, N., Reiter, M.H. Weil, D. and Standart, N. (2007). CPEB interacts with an ovary-specific EIF4E and 4-ET in early *Xenopus* oocytes. *J. Biol. Chem.* 282, 37389-37401.
- Minshall, N., Kress, M., Weil, D. and Standart, N. (2009). Role of p54 RNA helicase activity and its C-terminal domain in translational repression, P-body localization and assembly. *Mol. Biol. Cell* 20, 2464-2472.
- Muller-McNicoll, M. and Neugebauer, K. M. (2013). How cells get the message: dynamic assembly and function of mRNA-protein complexes. *Nature Rev. Gen.* 14, 275-287.
- Murray, M.T., Schiller, D.T. and Franke, W.W. (1992) Sequence analysis of cytoplasmic mRNA-binding proteins of *Xenopus* oocytes identifies a family of RNA-binding proteins. *Proc. Natl. Acad. Sci. USA* 89, 11-15.
- Nakamura, Y., Tanaka, K.J., Miyauchi, M., Huang, L., Tsujimoto, M. and Matsumoto, K. (2010). Translational repression by the oocyte-specific protein P100 in *Xenopus*. *Dev. Biol.* 344, 272-283.
- Ryan, J. P., Llinas, A. J., White, D. A., Turner, B. M. and Sommerville, J. (1999). Maternal histone deacetylase is accumulated in the nuclei of *Xenopus* oocytes as protein complexes with potential enzyme activity. *J. Cell Sci.* 112, 2441-2452.
- Sheets, M.D., Fritz, B., Hartley, R.S. and Zhang, Y. (2010). Polyribosome analysis for investigating mRNA translation in *Xenopus* oocytes. *Methods* 51, 152-156.

- Smillie, D.A. and Sommerville, J. (2002). RNA helicase p54 (DDX6) is a shuttling protein involved in nuclear assembly of stored mRNP particles. *J. Cell Sci.*, 115, 395- 407.
- Sommerville, J. (1990). RNA-binding phosphoproteins and the regulation of maternal mRNA in *Xenopus*. *J. Reprod. Fert. Suppl.* 42, 225-233.
- Sommerville, J. (1999). Activities of cold-shock domain proteins in translation control. *Bioessays*, 21, 281-297.
- Sommerville, J. (2010). Using oocyte nuclei for studies on chromatin structure and gene expression. *Methods* 51, 157-164.
- Sommerville, J. and Lodomery, M. (1996). Transcription and masking of mRNA in germ cells: involvement of Y-box proteins. *Chromosoma* 104, 469-478.
- Soop, T., Nashchekin, D., Zhao, J, Sun, X., Alzhanova-Ericsson, A. T., Björkroth, B., Ovchinnikov, L. and Daneholt, B. (2003). A p50-like Y-box protein with a putative translational role becomes associated with pre-mRNA concomitant with transcription. *J Cell Sci.* 116, 1493-503.
- Tanaka, K.J., Ogawa, K., Takagi, M., Imamoto, N., Matsumoto, K. and Tsujimoto, M. (2006). RAP55, a cytoplasmic mRNP component, represses translation in *Xenopus* oocytes. *J. Biol. Chem.* 281, 40096-40106.
- Weston, A. and Sommerville, J. (2006). Xp54 and related (DDX6-like) RNA helicases: roles in messenger RNP assembly, translation regulation and RNA degradation. *Nucleic Acids Res.* 34, 3082-3094.
- Yurkova, M. S. and Murray, M. T. (1997). A translation regulatory particle containing the *Xenopus* oocyte Y-box protein mRNP3+4. *J. Biol. Chem.*, 272, 10870-10876.

Figure legends

Fig. 1. Identification and expression of *xRAPB* (A) Immunoblot of poly(A)⁺RNP fractions from oocytes of *Xenopus laevis* and *Pleurodeles waltl* reacted with guinea pig anti-RAP55 and rabbit anti-Xp52. (B) Alternative designations of the three *Xenopus* Scd6 proteins described to date (left panel) and their percentage identities (right panel). (C) Comparison of expression through oocyte stages of Xp52/*xRAPB* and the RT-PCR products of the mRNA encoding *xRAPB*. (D) Immunostaining of ovary section with anti-*xRAPB* showing reaction with stages I – IV. Perimeters of the stage III and IV oocytes are indicated by white outlines. Bar indicates 200 μm. (E) Immunoblot of extracts from early-stage oocytes and progesterone matured oocytes, unbound (UB) and bound (B) by oligo(dT)- (cellulose. Lysates were obtained in the presence of 2mM Mg₂Cl or 5 mM EDTA. The transfer was reacted serially with anti-*xRAPB*; anti-Xp54; anti-YB2; anti-CPEB; anti-ERK2 and anti-phosphorylated MAPkinase (pMAPK). (F) Immunoblot of Cs₂SO₄ density gradient fractions of poly(A)⁺ RNP reacted with antibodies reacting with YB2, Xp54 and *xRAPB*. An immunoblot of the poly(A)⁺ RNP peak fraction taken from a CsCl density gradient, reacted with the same antibodies, is shown for comparison (right panel). Slot blots of RNA extracted from the same fractions from parallel gradients (lower panels) were reacted with ³²P-labelled antisense probes recognizing the mRNAs of nucleolin and histone deacetylase (HDAC).

Fig. 2. Interactions of *xRAPB* and *xRAPA* with Xp54. (A) Autoradiograph of an SDS-PAGE gel showing the ³⁵S-labelled recombinant proteins synthesized and labelled by coupled transcription/translation using cloned cDNAs in a reticulocyte lysate system. (B) Immunoprecipitations of ³⁵S-labelled *xRAPB*/Xp54 and *xRAPA*/Xp54 mixes with immobilized anti-Xp54 and anti-*xRAPB*. Bound (B) and unbound (UB) fractions. (C) Immunostained transfers from SDS-PAGE gels of oocyte poly(A)⁺ RNP, untreated and u.v.-cross-linked (UV) and with subsequent digestion with ribonuclease A (RNase). Putative, cross-linked Xp54/*xRAPB* heterodimers (~110 kDa) are recognized by anti-Xp54 and anti-*xRAPB*. Material recovered as a pellet from heat-treated poly(A)⁺ RNP (HTP) was raised in 8M urea and renatured by serial dilution into HB prior to crosslinking. The gel transfer, reacted with both antibodies together, shows a single discrete RNase-resistant band at ~110 kDa. The two other major mRNP proteins, YB2a/b, are not detected in cross-linked complexes with this same mobility. RNA/protein complexes resolved by RNase treatment are indicated (arrows).

Fig. 3. Complementation of *xRAPB* and *Xp54* in the formation of mRNP particles.

(A) Recombinant proteins produced from expression vectors used in this study. **(B)** Comparison of the rates of production of the epitope-tagged proteins, T7-*Xp54* and myc-*xRAPB*, after injection of the vectors into the nuclei of mid-stage oocytes, with the levels of endogenous proteins (endo-*Xp54* and endo-*xRAPB*). **(C)** Time course of translation *in vivo* from RNA transcripts encoding myc-tagged *xRAPB*, with and without co-translation of *Xp54*. The RNA was injected into the cytoplasm of mid-stage oocytes. **(D)** Immunoprecipitation from lysates of oocytes co-expressing myc-*xRAPB* and T7-*Xp54*. Expression vectors encoding the epitope-tagged proteins were injected into the nuclei of mid-stage oocytes, which were incubated for 36 h before extraction. Proteins were unbound (UB) or bound (B) to immobilized anti-myc, anti-T7, anti-*xRAPB*, anti-*Xp54* or non-immune serum (NI) and separated by SDS-PAGE. The transfer was reacted serially with anti-myc and anti-T7. Note that in the second lane of the anti-T7 panel the protein has mainly tracked to the edges. **(E and F)** Sedimentation analysis of mRNP particles formed during the co-expression of myc-*xRAPB* and T7-*Xp54* and myc-*xRAPA* and T7-*Xp54*. Glycerol gradient fractions were separated by SDS-PAGE and immunoblotted using first anti-myc, then anti-T7. Equal volumes of extracts were pre-treated with ribonuclease A (+RNase) prior to sedimentation. Ribosomal monomers sediment to the bottom of the centrifuge tubes, the pellet also containing larger complexes (80S+).

Fig. 4. Effects of knock-down and over-expression of *xRAPA* and *xRAPB* on translation rate. **(A)** Effect of antisense morpholinos (a/s MOs) recognizing tagged epitope sequences on co-expressed myc-*xRAPB* and T7-*Xp54*. Vector injections as for Fig. 3C with MO injections after 12 h. **(B)** Effect of a/sMOs recognizing the translation start sites of endogenous *xRAPB* and *Xp54* at 24 and 48h after cytoplasmic injection into mid-stage oocytes. Control is a random sequence MO. **(C)** Effect of a/sMOs recognizing *xRAPA* (A), *xRAPB* (B) and *Xp54* (P) on the rate of amino acid incorporation compared with control MO (C). Oocytes injected with MOs were incubated for 12 h before addition of [³⁵S]-methionine to the medium. Oocytes from each set were recovered at hourly intervals and processed to obtain percentage of radioactivity incorporated into protein. Data from three separate experiments were used to obtain means and standard deviations. **(D)** Autoradiographs of SDS-PAGE separated proteins were also obtained. A stained gel track (St) is shown to represent the total protein profile. Track density measurements taken from

autoradiographs representing four separate experiments were analysed and shown in the table (right). Numbers represent means and standard deviations. **(E)** As for **(C)** but with injection of expression vectors replacing MO injection. **(F)** As for **(D)** but showing results from over-expression of Xp54 (P) and xRAPB (B), and also from co-expression of Xp54 and xRAPB (PB). Bands attributed to the ectopically-expressed proteins (white spots and arrows) were subtracted from measurement of intensity totals. Numbers in the table (right) represent data from three separate experiments.

Fig. 5. Comparison in size distribution of mRNP particles containing xRAPA and xRAPB. **(A)** Sedimentation analysis of mRNP particles in extracts from mid-stage oocytes expressing either myc-xRAPA (upper panels) or myc-xRAPB (lower panels). Gradient fractions were separated by SDS-PAGE and immunoblotted with anti-myc, anti-Xp54 and anti-YB2 comparing the fastest sedimenting mRNP fractions containing myc-xRAPA (broken box) with those containing myc-xRAPB (solid box). **(B)** As **(A)** but with 5mM EDTA replacing 2 mM Mg²⁺. Peak sedimentation of ribosomal monomers (80S) and subunits (60S and 40S) are indicated as rate markers. **(C)** Sedimentation analysis of mRNP particles in extracts from mid-stage oocytes expressing only endogenous proteins. Gradient fractions separated by SDS-PAGE and immunoblotted with anti-xRAPB, anti-Xp54 and anti-YB2. Fractions of mRNP lacking xRAPB are highlighted (broken box). RNA extracted from aliquots of each of the gradient fractions was applied to a membrane by slot-blotting, the blot subsequently being hybridized with radiolabelled probes, antisense to mRNA encoding oocyte-specific β -tubulin and cyclin B1. Autoradiographs of the blots are shown (bottom panels). **(D)** As **(C)** but with 5mM EDTA replacing 2 mM MgCl₂. **(E)** As **(C)** except extract from early-stage oocytes. **(F)** As **(A)** except with extract from maturing oocytes (6 h after progesterone) expressing myc-xRAPB but showing a lack of xRAPB in post-80S fractions (broken box).

Fig. 6. Analysis of mRNAs immunoprecipitated (IP) by anti-myc from extracts from oocytes expressing myc-xRAPA or myc-xRAPB. RNA extracted from unbound (UB) and bound (B) fractions was used as templates for RT-PCR amplification using gene-specific primers for oocyte-specific genes. Represented here are: (a) mRNAs that are expressed as protein starting from early oogenesis: structural proteins, β -tubulin and nuclear actin (N-actin); translation components, eIF1 α and ribosomal protein L14; and stored enzymes,

histone deacetylase (HDACm); (b) stored mRNAs specifically directed to subcellular compartments, Xcat2/Nanos1 and Vg1; (c) stored mRNAs encoding proteins required for oocyte maturation, cyclin B1 and c-mos; (d) stored mRNA translated in eggs, D7; (e) stored mRNAs translated during early embryogenesis, mRNP protein YB1 and linker histone H1M. Products are separated on 1.5% agarose gels. Ribosomal RNAs (28S+18S and 5S) isolated from the same IP fractions are also shown (bottom panels).

ACCEPTED MANUSCRIPT




Figure 1

ACCEPTED




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6

ACCEPTED MANUSCRIPT

Highlights

- The Scd6/Lsm14b protein *xRAPB* is expressed during early oogenesis in *Xenopus*.
- *xRAPB* interacts with the DDX6 helicase Xp54 in poly(A)⁺mRNP particles.
- *xRAPB*-associated mRNAs are predisposed for translation or intra-cell translocation.

ACCEPTED MANUSCRIPT